Lamicone ZN Tablet contains a combination of Lamivudine 150mg, Zidovudine 300mg, and Nevirapine 200mg, a highly effective antiretroviral therapy (ART) formulation indicated for the management of HIV infection. It helps suppress viral replication, control viral load, and support immune system function in HIV-positive patients.
The combination works synergistically: Lamivudine and Zidovudine inhibit reverse transcriptase, while Nevirapine blocks viral replication at a different site. Together, they provide comprehensive viral suppression, improving immune function and long-term health outcomes.
For distributors and healthcare suppliers, Lamicone ZN Tablet is a high-demand ART product, widely prescribed in HIV clinics, hospitals, and infectious disease centers. The increasing prevalence of HIV and need for effective combination therapy ensure continuous demand throughout urban and rural healthcare networks.
Adding Lamicone ZN Tablet to your antiretroviral and viral suppression segment provides strong opportunities in pharmacies, hospital supply chains, HIV care centers, export markets, and third-party manufacturing. Its clinically proven efficacy, patient adherence profile, and broad therapeutic application make it a valuable addition for pharmaceutical distribution.
Some common side effects include headache, nausea, fatigue, diarrhea, and skin rash. Serious adverse effects, although rare, may include liver toxicity, lactic acidosis, anemia, neutropenia, or severe hypersensitivity reactions. Patients should immediately report any unusual or persistent symptoms to their healthcare provider.
Lamicone ZN Tablet is indicated for the management of HIV-1 infection in adults and adolescents. It helps in reducing viral load, increasing CD4 cell counts, and delaying the onset of HIV-related complications. This combination therapy is often prescribed as part of first-line ART regimens for effective and sustained viral suppression.
Before taking Lamicone ZN Tablet, patients should inform their doctor of any liver or kidney conditions, allergies, or co-existing infections. Therapy should not be interrupted abruptly, as it may result in viral rebound and the development of drug resistance. Regular monitoring of liver and kidney function, blood counts, and viral load is recommended during treatment.
Store Lamicone ZN Tablet in a cool, dry place, away from direct sunlight and moisture. Keep the tablets out of reach of children, and ensure the container is tightly closed. Do not use the medication beyond its expiration date.